Cost-Effectiveness of Adjuvanted Influenza Vaccine Compared with Standard and High-Dose Influenza Vaccines for Persons Aged ≥50 Years in Spain
In the model, aQIV dominated QIVe and HD-QIV, demonstrating that aQIV use would be cost-saving for persons aged ≥50 years who are at high risk of influenza complications.
Authors
- Alberto Pérez-Rubio
- Javier Sánchez (ORCID: https://orcid.org/0000-0003-2727-1479)
- Alfonso Muriel (ORCID: https://orcid.org/0000-0002-4805-4011)
- S. Márquez-Peláez (ORCID: https://orcid.org/0000-0003-1911-748X)
- Jesús Ruiz-Aragón (ORCID: https://orcid.org/0000-0001-6530-5823)
- Joaquin Mould-Quevedo (ORCID: https://orcid.org/0000-0003-4847-5956)
- Roberto Flores (ORCID: https://orcid.org/0000-0002-9856-8010)
- Piedad Alvarez
Institutions
- Seqirus (United States) (US)
- Hospital Universitario Puerta del Mar (ES)
- Hospital Clínico Universitario de Valladolid (ES)
- Universidad Pablo de Olavide (ES)
Publication Details
- Journal
- Vaccines
- Published
- 2025-03-19
- DOI
- https://doi.org/10.3390/vaccines13030323
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00